20 results about "Clinical disease" patented technology

The application discloses a nanobody targeting Claudin 18.2 and an application thereof, and belongs to the technical field of molecular biology. In view of the unique advantages of the nanobody in the prior art, the application provides a nanobody targeting Claudin 18.2, wherein the amino acid sequence of the nanobody is shown as SEQ ID NO. 1; the nanobody has strong affinity to 293T-Claudin 18.2 positive cells and can be combined with the Claudin 18.2 protein expressed on the cell surface. The nanobody targeting Claudin 18.2 provided by the application can be prepared by large-scale expression of an in-vitro engineering bacterium, can be applied to preparation of a protein detection antibody or a therapeutic antibody, can be used for in-vitro and in-vivo detection of tumor tissues expressing Claudin 18.2, and has important commercial value in clinical disease diagnosis and treatment.

This invention discloses a conductive hydrogel, its preparation method, and its applications. The conductive hydrogel's raw materials include hydroxypropyl cellulose, hyaluronic acid, acrylamide, and a conductive agent; the conductive agent includes at least one selected from lithium chloride, potassium chloride, sodium chloride, sodium sulfate, and potassium sulfate. This conductive hydrogel utilizes the liquid-phase transition characteristics of hydroxypropyl cellulose, combined with acrylamide, hyaluronic acid, and lithium chloride to achieve respiratory and body temperature monitoring. This conductive hydrogel exhibits good conductivity and can detect different types of respiration, providing valuable monitoring for the monitoring and development of clinical diseases. Simultaneously, the synergistic effect of the combined hyaluronic acid, acrylamide, and lithium chloride adjusts the lower critical dissolution temperature of hydroxypropyl cellulose to 37°C, causing the hydrogel to change from transparent to opaque at 37°C, enabling real-time temperature and respiratory monitoring for febrile patients in clinical settings.

This invention discloses a system for predicting the risk of recurrence after lumbar disc herniation surgery based on domain offset correction, relating to the fields of medical data processing and clinical disease risk prediction technology. The system acquires multimodal clinical and imaging feature vectors and follow-up outcome data from training and independent validation cohorts. It trains a center classifier to quantify and correct for differences in multi-center data distribution, calculates and normalizes the importance weights of each training case, trains a survival analysis base learner based on the processed weights, and performs stacking and ensemble integration. The final deployment model is determined by combining the independent validation case cohort. The final deployment model is then used to infer the risk of recurrence in target patients after lumbar disc herniation surgery, outputting individualized recurrence risk scores, risk stratification, and recurrence-free survival curves. This improves the robustness and reliability of the risk prediction system in cross-center scenarios and is suitable for follow-up management and clinical decision support after lumbar disc herniation surgery.

In one aspect, the disclosure relates to compounds that behave as molecular glue degraders (MGDs) and methods of making and using same. In various aspects, the disclosed compounds are useful for modulating PPIL4 activity through targeted degradation. In various aspects, the compounds are useful for treating medulloblastoma and / or acute lymphoblastic leukemia (ALL). In further aspects, the present disclosure relates to methods of making the disclosed compounds, pharmaceutical compositions comprising the disclosed compounds, and methods of treating various clinical conditions and disorders using the same, such as T-cell acute lymphoblastic leukemia. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Provided are pharmaceutical compositions comprising combinations of drugs, including products of manufacture and kits, and methods for using them, for treating, preventing, ameliorating, slowing the progress of, decreasing the severity of or preventing a coronavirus infection, or an infection caused by a virus in the subfamily Orthocoronavirinae, or a virus in the family Coronaviridae, or a virus in the order Nidovirales. In alternative embodiments, combinations, or cocktails, of a drug or drugs as provided herein are administered either enterally, parenterally and / or by inhalation. In alternative embodiments, combinations, or cocktails, of drugs as provided herein are used to block intracellular metabolic pathways and prevent progression of the infection to clinical illness and death. In alternative embodiments, novel aerosol or powder formulations for inhalation are provided.

The application discloses a protein for human P / Q type VGCC autoantibody detection and application, relates to the technical field of autoantibody detection, and the protein is a VGCC6 protein, and the amino acid sequence is shown as SEQ ID NO:6. In view of the clinical diagnosis demand of Lambert-Eaton myasthenic syndrome and other diseases related to the antibody, the protein provides strong support for early screening, diagnosis and disease condition monitoring of clinical diseases, fills the short board of the existing detection technology, and promotes the improvement of the diagnosis and treatment level of related autoimmune diseases.

The application discloses a biological age evaluation method and system based on whole life cycle DNA methylation and application, and belongs to the technical field of bioinformatics. First, the obtained original DNA methylation data is subjected to quality control and standardization processing; then, differential methylation sites significantly related to calendar age are screened as features; next, taking calendar age as a target variable, a regression model is constructed by adopting a LightGBM gradient boosting framework to obtain a methylation clock model; subsequently, the model is used to predict the DNA methylation age of an individual, and an epigenetic age acceleration value is calculated based on the deviation of the DNA methylation age from the calendar age; finally, the age acceleration value is subjected to correlation analysis with health or physiological indexes in different life stages, so as to evaluate the biological aging state of the individual and predict related health risks. The application covers the whole life cycle, is suitable for Chinese population, and can provide an effective tool for clinical disease risk prediction, health management and anti-aging intervention effect evaluation.

The application discloses a single-domain antibody targeting carcinoembryonic antigen and application thereof, and belongs to the technical field of molecular biology. In view of the unique advantages of the single-domain antibody in the prior art, the application provides a single-domain antibody targeting carcinoembryonic antigen, wherein the amino acid sequence of the single-domain antibody targeting carcinoembryonic antigen is shown as SEQ ID NO. 1; the single-domain antibody targeting carcinoembryonic antigen can specifically combine with carcinoembryonic antigen; compared with a traditional antibody, the single-domain antibody has smaller molecular weight and retains high efficient affinity; and after being expressed by coupling with a streptavidin SA monomer, the single-domain antibody can be used as an immunohistochemical detection antibody. The single-domain antibody targeting carcinoembryonic antigen provided by the application can be prepared by being expressed in a large amount by an in-vitro engineering bacterium, can be applied to preparation of a protein detection antibody, and has important commercial value in clinical disease diagnosis.

This invention relates to the field of pharmaceutical and chemical intermediates technology, and discloses a novel class of substituted phenylethyl-O-β-D-glucuronide compounds. These compounds are generated using substituted phenylethanol as a substrate and 1-fluoro-D-glucuronic acid as a glycosyl donor, catalyzed by β-glucuronyltransferase derived from *E. coli*. The process yield can reach over 95%, and the reaction conditions are mild and environmentally friendly. Substituted phenylethyl-O-β-D-glucuronide can be efficiently used for the determination of β-glucuronidase activity, and its applications are wide-ranging and reliable. The product can meet the needs of pharmaceutical, food, and other fields for β-glucuronidase activity control. It can be used for enzyme activity detection in the auxiliary diagnosis of clinical diseases, and also for enzyme quality control in fruit juice clarification processes in the food industry, drug precursor activation, and glycan structure analysis in the biopharmaceutical field. The product structure has been verified to be accurate by mass spectrometry and 1H NMR spectroscopy, and enzymatic hydrolysis experiments have confirmed its reliable application.

This invention provides a mass tag for mass flow cytometry, its preparation method, and its application. The mass tag provided by this invention has the chemical structure shown in Formula 1. The compound shown in Formula 1 provided by this invention offers a new channel for CyTOF single-cell analysis, suitable for the detection of various biomarkers such as live cells and proteins. It is of great significance for more in-depth and comprehensive analysis of changes in various cell subtypes and their proportions, and for predicting the changing trends of clinical disease courses, showing good clinical application prospects and significant social benefits.

The application belongs to the technical field of proteomics and clinical disease screening, and relates to application of a combination of plasma proteins in screening of pancreatic cancer. The application is based on mass spectrometry quantitative proteomics technology, screens and determines a marker combination composed of four plasma proteins of GCLC, ALAD, HAGH and SORD, and comprehensively analyzes relative abundance of the marker combination through a binary Logistic regression model to distinguish pancreatic cancer patients from healthy people. Experimental results show that the protein combination has high sensitivity, specificity and area under curve (AUC) in a screening set and an independent verification set, and has good stability and repeatability. The method has the advantages of non-invasiveness, feasible operation and applicability to population screening by taking plasma as a detection sample, and can provide a new technical means for early screening of pancreatic cancer.

This invention belongs to the field of medical image processing technology, specifically relating to a voxel-level spatiotemporal topology measurement system for rheumatoid interstitial lung disease. First, it acquires multi-temporal images of the patient and uses a differential homeomorphic deformation registration algorithm to eliminate differences in respiration and body position, constructing a four-dimensional voxel sequence set tensor. Second, it applies continuous homology theory to extract the Betti number reflecting the connectivity of fibrotic pores and cavities, generating a topological feature tensor field, and calculates continuous transformation derivatives to measure the spatiotemporal evolution vector field of lesion migration to the fibrotic state. Finally, it maps this vector field to a preset model, quantifies the comprehensive topological destruction rate and spatial heterogeneity index of microstructures, outputs risk levels, and generates a visual heatmap. This invention, by eliminating spatial misalignment across temporal images and overcoming the limitations of single grayscale assessment, achieves accurate quantitative measurement of the topological evolution process of microscopic lung tissue, thus providing intuitive and reliable decision support for clinical disease assessment and intervention.

Invasive fungal disease (IFD) constitutes an increasing health concern due to growing numbers of patients at risk for opportunistic fungal infections. Among the fungi capable of inducing opportunistic infections the yeast Candida albicans is clinically the most important. Immune evasion proteins like the pH-regulated antigen 1 (Pra1) and the translation elongation factor 1 (Tef1), which are expressed on the fungal surface and are also secreted, are major drivers of pathogenicity. Therefore, novel monoclonal antibodies (mAb) binding these proteins have been developed. In an in vivo mouse model of high-dose septic C. albicans infection, therapeutic application of mAb against Pra1 reduced clinical symptoms of the disease. Prophylactically, mAb against Tef1 protected mice from clinical disease and prolonged survival. The mABs of the present invention may also be efficacious in patients at risk or with already established IFD.

Methods for characterizing disease activity in patients with systemic lupus erythematosus (SLE). These methods include obtaining blood, serum, plasma, or urine samples from the patient; assessing the expression of biomarkers selected from IFN-α, IL-10, BlyS, IL-7, IFN-γ, TRAIL, IL-15, IP-10 / CXCL10, and IL-4 in the samples; assessing the expression of inflammatory mediators selected from TNFRII, resistin, and osteopontin (OPN) in the samples; assessing SLE-related autoantibody-specific biomarkers selected from dsDNA, chromatin, RiboP, Ro / SSA, La / SSB, Sm, SmRNP, and RNP in the samples; and calculating the Lupus Disease Activity (Immune) Index (LDAII / L-DAI) score. The LDAII / L-DAI score can distinguish between active and low lupus disease activity. Treatment methods are also provided, including administration after determining that the patient has a prognostic risk of transitioning to classified SLE but before reaching the clinical disease classification.

This invention provides a method for preparing Astragalus colloidal phase, comprising the following steps: Preparing Astragalus decoction: Astragalus slices are extracted by reflux with water, filtered, and concentrated to obtain a standard Astragalus decoction; Phase separation: The standard Astragalus decoction is subjected to differential centrifugation and dialysis to obtain multiple physical phases, including a precipitate phase, a suspension phase, and a colloidal phase; Screening of active phases: The efficacy of each phase is evaluated using a renal edema model, and the phase with significant diuretic and anti-edema activity is selected as the Astragalus colloidal phase. The prepared Astragalus colloidal phase is a brownish-yellow transparent system with a particle size of 88.928 ± 0.683 nm and a PDI of 0.3516 ± 0.0162; the microstructure consists of spherical aggregates with a particle size distribution range of 30-200 nm; the yield is 23%. The colloidal phase of Astragalus membranaceus of this invention has nephroprotective and diuretic effects, and can be used in the preparation of drugs for treating renal edema. It provides a new and highly effective drug option for the treatment of related clinical diseases and the development of a new generation of innovative traditional Chinese medicine drugs for treating renal edema.

This invention relates to a progressive pathological animal model for drug evaluation and its construction method, belonging to the field of experimental animal model technology. Addressing the shortcomings of existing models, such as their inability to simulate progressive clinical disease courses, low model success rate, large individual variability, and low fit with clinicopathological features, this invention employs a sequential three-stage synergistic induction modeling method. This method sequentially induces basal metabolic abnormalities, subclinical cardiorenal injury, and progressive cardiorenal fibrosis, accurately matching the natural course of human diseases. This method is simple to operate, requires no complex surgery, and produces a model with a high model success rate, low mortality rate, good uniformity, and a high degree of fit between pathological features and clinical findings. It can be used for screening drugs for the treatment of this disease, evaluating drug efficacy, and studying the mechanism of action.

A compound of formula I, or a stereoisomer, tautomer, N-oxide, hydrate, isotope-substituted derivative, or solvate thereof, or a pharmacologically acceptable salt thereof, or a mixture thereof, of a prodrug thereof. The compound of formula I is a kinase inhibitor which can be used for treating clinical disorder caused by DDR deficiencies, such as cancers.

Disclosed are a small molecule binding ligand of a α-synuclein aggregate, and a preparation method therefor and a use thereof. The small molecule binding ligand of a α-synuclein aggregate is a compound shown in the following general formula (I). The compound can specifically and strongly bind to a α-synuclein aggregate and can be used for detecting / dyeing the α-synuclein aggregate and Lewy body in the brain of a patient, and a radioactive marker of the compound can be used as an imaging tracer probe required in image examination technologies such as PET and SPECT for clinical disease diagnosis. The compound is further used for preparing the radioactively marked imaging tracer probe or a composition thereof. Diseases associated with α-synuclein misfolding and abnormal aggregation comprise Parkinson's disease, Parkinson's disease dementia, Alzheimer's disease, multiple system atrophy, Lewy body dementia, etc.

The present disclosure provides a fusion protein capable of improving base editing activity and reducing an off-target level, and relates to the technical field of biological technologies. In the present disclosure, a degradation system based on a tDeg fusion protein is first introduced into a base editing system to obtain a novel base editing system capable of improving the base editing efficiency while reducing the off-target level. Further, a degron sequence and a RNA-binding polypeptide are fused with a base editing module of a base editor to form a fusion protein and meanwhile Pepper RNA is introduced into a loop region of sgRNA, so as to obtain the base editing system of the present application. The base editing system with high efficiency and low off-target rate constructed in the present disclosure will further promote wide base editing tool application, especially in gene therapy and clinical disease treatment.

This invention discloses a method for preparing composite immunohistochemical cell quality control samples. The method disclosed in this invention is applicable to the preparation of immunohistochemical quality control samples targeting multiple proteins, exhibiting strong versatility. Furthermore, this method enables multi-level, multi-gradient controls within a single paraffin block, significantly reducing the cost and complexity of immunohistochemical detection, and has broad application prospects in clinical disease diagnosis.